Logo
x

Search category

Subscribe Now

Active psoriatic arthritis

UCB Reports Interim Results of Bimekizumab in P-III BE OPTIMAL Study for the Treatment of Active Psoriatic Arthritis

UCB Reports Interim Results of Bimekizumab in P-III BE OPTIMAL Study for the Treatment of Active Psoriatic Arthritis

  • November 22, 2021
Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER-1 & 2 Trials for the Treatment of Active Psoriatic Arthritis

Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER-1 & 2 Trials for the Treatment of Active Psoriatic Arthritis

  • November 2, 2021
AbbVie-Skyrizi (risankizumab) Receives CHMP's Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the EU

AbbVie-Skyrizi (risankizumab) Receives CHMP's Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the...

  • October 18, 2021
Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis

Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis

  • March 17, 2021
AbbVie Reports Results of Skyrizi (Risankizumab) in P-III Studies for Active Psoriatic Arthritis

AbbVie Reports Results of Skyrizi (Risankizumab) in P-III Studies for Active Psoriatic Arthritis

  • January 6, 2021
Janssen's Tremfya (guselkumab) Receives the US FDA's Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis

Janssen's Tremfya (guselkumab) Receives the US FDA's Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthriti...

  • September 11, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.